Subtype
Renal Cell Carcinoma
CI-CAN-00006578RCCExplore in graph →
375 active trials17 approved drugs60 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006578RCCExplore in graph →
Clinical trials
1,621 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (276)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00056537 | ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer | completed | Phase 1 | 44 | Active Biotech ABINDUSTRY | 3 | Aug 27, 2014 | clinicaltrials |
| NCT00384969 | Sorafenib and RAD001 Renal Cell Carcinoma | completed | Phase 1 | 21 | University of California, San FranciscoOTHER | 1 | Aug 18, 2014 | clinicaltrials |
| NCT00265135 |
| A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma |
| completed |
| Phase 1 / Phase 2 |
| 68 |
| Centocor, Inc.INDUSTRY |
| 4 |
| Jul 3, 2014 |
| clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT01198184 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00684996 | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT01381822 | Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors(TH-CR-410) | unknown | Phase 1 | 58 | Threshold PharmaceuticalsINDUSTRY | 1 | Apr 21, 2014 | clinicaltrials |
| NCT01243359 | Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies | completed | Phase 1 | 6 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00356460 | Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma | completed | Phase 1 | 29 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00890747 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2014 | clinicaltrials |
| NCT00348699 | AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery | completed | Phase 1 | 68 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00891475 | Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients | completed | Phase 1 / Phase 2 | 114 | Kidney Cancer Research BureauOTHER | 1 | Feb 13, 2014 | clinicaltrials |
| NCT01677390 | A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma | terminated | Phase 1 | 4 | Seagen Inc.INDUSTRY | 1 | Jan 28, 2014 | clinicaltrials |
| NCT01100619 | A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors | completed | Phase 1 | 40 | ExelixisINDUSTRY | 1 | Sep 19, 2013 | clinicaltrials |
| NCT01079286 | Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers(I-NET) | completed | Phase 1 | 18 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jul 15, 2013 | clinicaltrials |
| NCT00635791 | Phase I Study of Vorinostat and Sorafenib in Advanced Cancer | completed | Phase 1 | 36 | University of Colorado, DenverOTHER | 1 | Jun 20, 2013 | clinicaltrials |
| NCT00944905 | Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) | completed | Phase 1 | 46 | Bristol-Myers SquibbINDUSTRY | 1 | May 22, 2013 | clinicaltrials |
| NCT00112476 | Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00217542 | Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00089362 | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00272649 | Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer | completed | Phase 1 / Phase 2 | 22 | Argos TherapeuticsINDUSTRY | 2 | Mar 14, 2013 | clinicaltrials |
| NCT00937482 | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer | terminated | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Mar 8, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00816686 | A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer | terminated | Phase 1 | 7 | Astellas Pharma IncINDUSTRY | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00087984 | RNA-Loaded Dendritic Cell Cancer Vaccine | completed | Phase 1 / Phase 2 | 26 | Argos TherapeuticsINDUSTRY | 2 | Feb 18, 2013 | clinicaltrials |
| NCT00193258 | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 94 | SCRI Development Innovations, LLCOTHER | 0 | Jan 31, 2013 | clinicaltrials |
| NCT01114230 | A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer | completed | Phase 1 | 26 | Astellas Pharma IncINDUSTRY | 1 | Dec 12, 2012 | clinicaltrials |
| NCT00372853 | Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma | completed | Phase 1 | 28 | AstraZenecaINDUSTRY | 1 | Jun 6, 2012 | clinicaltrials |
| NCT01441388 | A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. | withdrawn | Phase 1 | 0 | PfizerINDUSTRY | 0 | Dec 20, 2011 | clinicaltrials |
| NCT00197860 | Dendritic Cell Based Therapy of Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 40 | Inge Marie SvaneOTHER | 1 | Nov 23, 2011 | clinicaltrials |
| NCT00563147 | A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma | completed | Phase 1 | 28 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 4, 2011 | clinicaltrials |
| NCT00113529 | Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 1 | Aug 29, 2011 | clinicaltrials |
| NCT00862303 | DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 100 | Fuzhou General HospitalOTHER | 1 | Mar 8, 2011 | clinicaltrials |
| NCT01254838 | Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma | completed | Phase 1 | — | Iwate Medical UniversityOTHER | 0 | Dec 7, 2010 | clinicaltrials |
| NCT01240005 | Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Qingdao UniversityOTHER | 1 | Nov 15, 2010 | clinicaltrials |
| NCT00422344 | A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma | completed | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 26, 2010 | clinicaltrials |
| NCT00351949 | IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC) | completed | Phase 1 | 24 | Immutep S.A.S.INDUSTRY | 1 | Jan 7, 2010 | clinicaltrials |
| NCT00625768 | Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma | completed | Phase 1 | 13 | Antisoma ResearchINDUSTRY | 2 | Aug 25, 2009 | clinicaltrials |
| NCT00389285 | Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 52 | ZymoGeneticsINDUSTRY | 1 | May 27, 2009 | clinicaltrials |
| NCT00890110 | Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib(rcc) | unknown | Phase 1 / Phase 2 | 13 | Hadassah Medical OrganizationOTHER | 0 | Apr 29, 2009 | clinicaltrials |
| NCT00095108 | Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer | completed | Phase 1 | 43 | ZymoGeneticsINDUSTRY | 1 | Mar 9, 2009 | clinicaltrials |
| NCT00043407 | CPG 7909 in Patients Wih Stage IV Renal Cell Cancer | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 0 | Feb 12, 2009 | clinicaltrials |
| NCT00421512 | A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients | completed | Phase 1 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 11, 2008 | clinicaltrials |
| NCT00001383 | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 | completed | Phase 1 | 52 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001683 | A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00056173 | Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 43 | Aptose Biosciences Inc.INDUSTRY | 1 | Jan 7, 2008 | clinicaltrials |
| NCT00417677 | A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 124 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 28, 2007 | clinicaltrials |
| NCT00006431 | Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA | unknown | Phase 1 | — | National Center for Research Resources (NCRR)NIH | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Aug 27, 2014source: clinicaltrials